ReviewCurrent pharmaceutical design2025
Long Non-coding RNAs as Key Modulators in Hypoxic-Ischemic Brain Injury: Implications for Neuroprotection.
Review in Current pharmaceutical design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Long non-coding RNAs (lncRNAs) are a complex and diverse group of transcripts, typically longer than 200 nucleotides, which do not encode proteins but play crucial roles in regulating gene expression. They exert their influence through various mechanisms, such as interacting with DNA, mRNA, and proteins, which allows them to modulate a wide array of biological processes. Recent studies have underscored the importance of lncRNAs in the development of the nervous system and the pathogenesis of neurological diseases, particularly in the context of hypoxic-ischemic brain injury. Hypoxic-ischemic brain injury, caused by reduced blood flow and oxygen supply to the brain, is a leading cause of long-term neurological deficits. This review delves into the emerging role of lncRNAs in hypoxic-ischemic brain injury, exploring how these non-coding RNAs influence critical molecular and cellular pathways involved in the brain's response to hypoxia-ischemia. Notable advancements, such as the identification of lncRNAs, like BC088414 and FosDT, highlight their dual roles as mediators of injury and potential therapeutic targets. Additionally, we discuss the feasibility of lncRNAs as biomarkers for early diagnosis and prognosis of hypoxic-ischemic brain injury. Despite these advancements, challenges remain in translating lncRNA research into clinical applications. Issues, such as delivery mechanisms, off-target effects, and the ethical considerations surrounding gene modulation, must be addressed. By synthesizing current research, this review aims to provide a comprehensive understanding of the multifaceted roles of lncRNAs in hypoxic-ischemic brain injury, paving the way for future research and novel therapeutic strategies targeting these non-coding RNAs in neurological disorders.
Indexed as
Identifiers
40264320What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.